US charges ex-Monsanto employee with stealing trade secrets for China
22-11-2019
rawf8 / Shutterstock.com
China has added 70 medicines to its national medical insurance catalogue, which will reduce the cost of the drugs by more than 60% on average, the National Healthcare Security Administration (NHSA) has said.
In an announcement on Friday, November 29, the NHSA said the price drop comes after “months-long” price negotiations with authorities, and will take effect on January 1.
Of the 70 agreed treatments, 22 are for the treatment of cancer.
“The administration has been actively negotiating with pharmaceutical companies to lower the prices of their products and reduce the financial burden on patients as part of the country's healthcare reform.
“In return, drugmakers will get their products onto the national insurance list, which helps increase sales volume,” the NHSA said.
Xiong Xianjun, head of the administration's medical service department, said some drugmakers had agreed to provide their drugs for the “lowest prices in the world for Chinese patients”.
Additionally, he said it was estimated that due to the major price cuts, the out-of-pocket amounts paid by patients will drop by between 80 and 95 percent," he said.
The NHSA said the country’s cancer patients are in urgent need of affordable treatment and are discouraged by prohibitive prices. As a result, some have resorted to purchasing generic, cheap versions from overseas to sustain treatment.
The newly-added cancer drugs include a foreign medication—Jakavi—that treats myelofibrosis, an acute form of bone marrow cancer, developed by Novartis.
Deng Yuexin, head of the market access department at Novartis Oncology in China, said the medication, priced at about 8,000 yuan ($1,138) for 60 tablets, will be sold at the world's cheapest price in China.
The company said it could not reveal how much of a discount it has granted to the Chinese market due to a confidentiality agreement with Chinese authorities.
"Last year, we failed to reach an agreement with the administration during the price negotiation due to shifts in our global market expansion strategy, which had saddened many of our Chinese patients," she said. "This time, they are bound to be over the moon."
Eight homegrown drugs also made it to the list, including Tyvyt, which targets lymph cancer. It was developed by Suzhou-based Innovent Biologics.
He Shiwen, an employee at Innovent, said the price of Tyvyt has been reduced by 64%.
"Even before the price cut, Tyvyt was significantly cheaper than its counterparts available on the Chinese market. The medication is now even more affordable for patients," he said.
Agreements have also been renewed for another 27 products already on the list, with an average price cut of 26.4 percent, Xianjun said.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
China, national medical insurance, National Healthcare Security Administration, cancer, drugs, lower prices, generics, Novartis